Maverix Medical, a company focused on revolutionizing the diagnosis and treatment of lung cancer, today announced that the U.S. Food and Drug Administration granted 510(k) clearance for the Maverix Narwhal™ Cryo System, a single-use flexible cryoprobe that requires no console — bringing cryobiopsy to the bronchoscopy suite without dedicated capital equipment.
Read More Maverix Medical, a company focused on revolutionizing the diagnosis and treatment of lung cancer, today announced the appointment of Carla Jung as Chief Executive Officer. Jung will lead the company's strategy, execution, and continued growth as Maverix scales its commercial organization and brings new products to market...
Read More
Lung cancer diagnostics and treatment developer Maverix Medical announced today that it appointed Carla Jung as its new CEO...
Read More
After launching late last year, the lung cancer-focused startup Maverix Medical is reaching for the sky with the acquisition of diagnostic developer Cirrus Bio.
Read More Maverix Medical, a dedicated lung cancer platform established by Ajax Health, KKR, and Hologic, Inc., today announced the acquisition of Cirrus Bio for an undisclosed amount.
Read More
Ajax creates turnkey innovation platforms for commercial-stage medtech players, and has partnered with investment firm KKR and medtech company Hologic to launch a new company.
Read More
KKR, a leading global investment firm, today announced a new platform established with investments from KKR and Hologic, Inc., named Maverix Medical.
Read More
Peripheral bronchoscopy is often performed to biopsy peripheral pulmonary lesions. Despite technological advancements to improve reach and access to the lung periphery, diagnostic yield has been inconsistent.
Read More
Despite growing experience using advanced guided techniques, the diagnostic yield of bronchoscopy for peripheral pulmonary lesions remains suboptimal, particularly for lesions adjacent to peripheral bronchi.
Read More